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July 2011280 Abstractsarteries. Overall, however, the data do not support a policy of routine
stenting of the celiac and SMA for treatment of CMI.
Safety of Stenting and Endarterectomy by Symptomatic Status in the
Carotid Revascularization Endarterectomy Versus Stenting Trial
(CREST)
Silver FL, Mackey A, Clark WM, et al. and the Crest Investigators. Stroke
2011;42:675-80.
Conclusion: For the primary Carotid Revascularization Endarterec-
tomy Versus Stenting Trial (CREST) end point of the composite of stroke,
death, and myocardial infarction, there are no significant differences be-
tween carotid artery stenting (CAS) and carotid endarterectomy (CEA) by
symptomatic status. Periprocedural stroke and death rates are significantly
lower for CEA in symptomatic patients. Nearly twice as many strokes
occurred in asymptomatic patients with CAS vs CEA (15 vs 8), but this did
not reach statistical significance.
Summary: This is a secondary analysis of CREST data. CREST inves-
tigated the safety and efficacy CAS vs CEA in patients with high-grade
carotid stenosis. A symptomatic patient was defined as having had appropri-
ate symptoms 180 days of randomization. The primary end point of
CRESTwas a composite of stroke, myocardial infarction, or death within the
periprocedural period or ipsilateral stroke up to 4 years. There were 1221
symptomatic and 1181 asymptomatic patients entered into CREST. For all
patients, the periprocedural aggregate of stroke, myocardial infarction, and
death did not differ between CAS and CEA (5.2% vs 4.5%; hazard ratio
[HR], 1.18; 95% confidence interval [CI], 0.82-1.68; P  .38). Rates of
stroke and death, however, were higher for CAS vs CEA (4.4% vs 2.3%; HR,
1.90; 95% CI, 1.21-2.98; P  .005). For symptomatic patients, periproce-
dural stroke and death rates were 7.0% 0.9% for CAS and 3.2% 0.7% for
CEA (HR, 1.89; 95% CI, 1.11-3.21; P  .02). For asymptomatic patients,
stroke and death rates were 2.5% 0.6% for CAS and 1.4% 0.5% for CEA
(HR, 1.88; 95% CI, 0.75-4.42; P  .15). Results were better in patients
aged 80 years vs those 80 years.
Comment: Every reasonable analysis of government-sponsored ran-
domized trials continues to indicate that CEA is superior to CAS for
treatment of patients with symptomatic carotid stenosis if the goal of the
procedure is to prevent stroke. Very significant questions remain about the
treatment of asymptomatic patients. The large majority of patients under-
going carotid intervention in the United States do so for asymptomatic
carotid stenosis. And yet, we really do not know the natural history of this
disease in the modern era with more advanced antiplatelet mediations, statin
medications, and better blood pressure control available now than was
available 20 years ago. However, these medications will only be effective if
the patients take them. What is needed is a three-arm trial in asymptomatic
patients with carotid artery stenosis: medical management alone vs medical
management combined with CEA vs medical management combined with
CAS. The anticipated number of events, the number of patients required,
and the number of centers required will likely be large for such a study.
However, given the demographics of carotid interventions in the United
States, the potential public health and economic effect of the results of such
a trial would be felt immediately.
Apolipoprotein (a) Isoforms and the Risk of Vascular Disease: A
Systematic Review of 40 Studies Involving 58,000 Participants
Erqou S, Thompson A, Angelantonio D, et al. J Am Coll Cardiol 2010;55:
2160-7.
Conclusion: Smaller apolipoprotein (a) (apo[a]) isoforms confer an
approximately twofold higher risk of ischemic stroke or coronary heart
disease than larger isoforms of apo(a).
Summary: Lipoprotein(a) (Lp[a]) is composed of a glycoprotein mol-
ecule, apo(a), and a low-density lipoprotein (LDL) particle. Apo(a) is
responsible for the properties of Lp(a). (Marcovina SM et al [Am J Cardiol
1998:82:57U-66U]; McLean JW et al [Nature 1987;330:132-7]). In-
creased circulating Lp(a) concentration is associated with increased risk of
coronary heart disease (CHD) and stroke and is independent of other
conventional risk factors for vascular disease, including total cholesterol
level. The overall additive risk of abnormalities of Lp(a) is only about
one-quarter that seen with LDL cholesterol level (JAMA 2009;302:412-
23). However, specific Lp(a) subtypes may confer higher cardiovascular risk.
If that is the case, analysis for Lp(a) subtypes may be useful in the stratifica-
tion of vascular risk. The authors postulated that Lp(a) particles associated
with smaller rather than larger apo(a) isoforms may result in higher cardio-
vascular risk. They analyzed information from 40 studies published between
January 1970 and June 2009 that reported an association between apo(a)
isoforms and the risk of ischemic stroke or CHD. This involved 11,396
patients and 46,938 controls in 36 studies that used comparable phenotyp-
ing and analytic methods to assess apo(a) isoform size. These studies yielded
a combined relative risk for CHD of 2.08 (95% confidence interval [CI],
1.67-2.58) for subjects with smaller vs larger apo(a) isoforms. There was
substantial heterogeneity among the studies (I2 85%; 95% CI, 80%-89%).
b
Meterogeneity was mainly explained by differences in analytical approaches
nd laboratory methods. Six studies of ischemic stroke used comparable
henotypic methods with a combined relative risk of 2.14 (95% CI, 1.85-
.97).
Comment: Apo(a) size heterogeneity is a function of a copy number
ariation of one protein domain, kringle IV type 2, the gene for which exists
n 5 to 50 identically repeated copies. Copy number variation of the gene
onfers marked heterogeneity in the molecular mass of the apo(a) isoform
Boffa MB [Clin Biochem 2004;37:333-43]). Apo(a) subtyping has been
linically limited because it adds a relatively modest incremental risk com-
ared with other biomarkers for cardiovascular disease. However, this study
ndicates there are subtypes of apo(a) that may be worth looking for. It will
eed to be determined whether smaller apo(a) isoforms have sufficient
elevance in determining vascular risk independent from Lp(a) concentra-
ion when compared to other more conventional risk factors for atheroscle-
osis.
arotid Artery Stenting Versus Carotid Endarterectomy: A Compre-
ensive Meta-Analysis of Short-Term and Long-Term Outcomes
conomopoulos KP, Sergentanis TN, Tsivgoulis G, et al. Stroke 2011;42:
87-92.
Conclusion: Long-term and short-term outcomes of carotid endarter-
ctomy (CEA) are both superior to those of carotid artery stenting (CAS),
ut there may be subgroups where results are more equivalent.
Summary: Before this meta-analysis, the most recent meta-analysis of
he results of CEA vs CAS was performed by Meier et al (BMJ 2010;340:
467). Since the Meier et al publication, there has subsequently been
ublication of the Carotid Revascularization Endarterectomy Versus Stent
rial (CREST), as well as publication of the long-term results of the Carotid
nd Vertebral Artery Transluminal Angioplasty Study (CAVATAS) and the
tent-Supported Percutaneous Angioplasty of the Carotid Artery Versus
ndarterectomy (SPACE) trial. This new meta-analysis was performed to
rovide short-term and long-term comparisons between CEA and CAS
sing all available data from published randomized trials. Short-term results
ere defined as 30 days. Analysis and long-term outcomes were depicted
ith hazard ratios for 1 year results.
Therewere 13 randomized trials incorporating3723CEAs and3754CAS
atients. CASwas associated with short-term elevated risk for stroke and “death
r stroke.” There was also a marginal trend towards higher death and “death or
isabling stroke” with CAS. Rates of cranial nerve injury and myocardial
nfarction were higher with CEA. With respect to long-term results, CAS was
ssociated with higher rates of stroke (pooled odds ratio, 1.37; 95% confidence
nterval, 1.13-1.65) and higher rates of “death or stroke” (pooled odds ratio,
.25; 95% confidence interval, 1.06-1.48). Results were replicated with pooled
azard ratios. The difference in long-term stroke rates was most apparent in
atients aged68 years, with little differences observed in rates in patients aged
68 years. There was no significant heterogeneity among trials. Additional
nalysis did not reveal any modifying effects mediated by symptomatic or
symptomatic status, distal protection devices, early termination of trials, area of
tudy origin, or CAS learning curve.
Comment: The frequently reported advantages of CEA over CAS in
reventing short-term risk of stroke are now reported to be continued in the
ong-term. There are, of course, still many questions regarding the use of CEA
rCAS.Wedonot knowwhich is better in patientswith acute stroke, nor dowe
now about long-term restenosis. Overall, CEA and CAS may be roughly
quivalent with regard to neurologic outcome in younger patients; however, if
he overall goal is to prevent stroke, CEA is more effective than CAS.
holesterol Efflux Capacity, High-Density Lipoprotein Function, and
therosclerosis
hera AV, Cuchel M, de la Llera-moya M, et al. N Engl J Med 2011;364:
27-35.
Conclusion: Cholesterol efflux capacity has a strong inverse relation-
hip with angiographic coronary artery disease and carotid intima-media
hickness independent of high-density lipoprotein (HDL) cholesterol level.
Summary: A strong inverse association exists between levels of HDL
holesterol and cardiovascular disease risk. Pharmacologic increases in HDL
holesterol have thus been postulated to reduce cardiovascular risk. How-
ver, an inhibitor of cholesteryl ester transfer protein (CETP) was found to
esult in a 72% increase in HDL cholesterol levels, but was associated with an
ncrease in the number of cardiovascular events (Barter PJ [N Engl J Med
007;357:2109-22]). This may be because HDL has marked heterogeneity
n particle composition that affects its biologic properties. Emphasis has
herefore shifted on not only measurement of HDL cholesterol levels but on
he development of a validated measure of HDL function (Vaisar T [J Clin
nvest 2007;117:746-56]). There may be many components of HDL-
ediated atheroprotection. The ability of HDL to promote reverse choles-
erol transport by accepting cholesterol from lipid-laden macrophages may
e important. This is termed “cholesterol efflux capacity” (Tall AR [J Intern
ed 2008;263:256-73]).
